The efficacy and safety of fexuprazan in treating erosive esophagitis: a phase III, randomized, double-blind, multicenter study.

Qianjun ZhuangAijun LiaoQingling HeChengxia LiuChangqing ZhengXing LiYouli LiuBangmao WangSide LiuYan ZhangRong LinHuixin ChenMin DengYanping TangChiyi HeWeijie DaiHaitao TangLei GongLiangping LiBaohong XuChangqing YangBingxi ZhouDongxing SuQinghong GuoBin LiYong Jian ZhouXiaoyang WangSujuan FeiHuili WuSichen WeiZhihong PengJianning WangYan Qing LiHong WangTianwei DengShigang DingFangfang LiMinhu ChenYing Lian Xiao

Published in: Journal of gastroenterology and hepatology (2024)

This study demonstrated noninferior efficacy of fexuprazan to esomeprazole in treating EE. The incidence of TEAEs was similar between fexuprazan and esomeprazole. Trial registration number NCT05813561.

Keyphrases

phase iii
double blind
placebo controlled
open label
clinical trial
phase ii
study protocol
risk factors
randomized controlled trial